ImmunoPrecise Antibodies (TSXV:IPA; OTCPINK:IPATF) announced it increased a previously announced non-brokered private placement financing to 5,100,000 shares for gross proceeds of up to $5,100,000.
As quoted in the press release:

All securities issued in connection with the private placement will be subject to a four‐month‐and‐one day statutory hold period. A finder’s fee may be payable on the private placement.
Proceeds of the financing will be used for the acquisition of U-Protein and working capital purposes.
Completion of the private placement remains subject to the approval of the TSX Venture Exchange.

Click here to read the full press release.

Source: www.newswire.ca